{
    "clinical_study": {
        "@rank": "51841", 
        "acronym": "OVARONKO", 
        "arm_group": [
            {
                "arm_group_label": "case group", 
                "arm_group_type": "Experimental", 
                "description": "Throughout the course of chemotherapy, patients were administered triptorelin (Diphereline SR 3 mg, Ibsen) in the form of i.m. injections, always once a month and simultaneously with the chemotherapy."
            }, 
            {
                "arm_group_label": "control group", 
                "arm_group_type": "No Intervention", 
                "description": "no intervention"
            }
        ], 
        "brief_summary": {
            "textblock": "Chemotherapy as one of the basic modalities of oncology treatment often leaves permanent\n      implications and among the most common is infertility as a result of irreversible gonadal\n      damage. This project sets the primary target to verify the protective effect GnRH analogues\n      administration to protect ovarian tissue during three different regimens of chemotherapy in\n      patients with Hodgkin disease (HD) in reproductive age."
        }, 
        "brief_title": "Prevention of Ovarian Function Damage by a GnRH Analogue During Chemotherapy in Hodgkin Lymphoma Patients", 
        "completion_date": {
            "#text": "January 2008", 
            "@type": "Actual"
        }, 
        "condition": [
            "Hodgkin Lymphoma", 
            "Hodgkin Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hodgkin Disease", 
                "Lymphoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "During the first two years of the project duration the curative anti-tumorous combined\n      treatment in fertile patients with Hodgkin disease diagnosis will be carried out. Patients\n      are to be divided into three groups according to the clinical stage of the disease and\n      treated with the three types of the chemotherapeutic regimens comparable with toxicity.\n      Patients will receive GnRH analogues during the chemotherapy for the gonadal protection by\n      the mechanism of foliculogenesis inhibition in pre-pubertal stage. At the end of successful\n      treatment according to stated criteria the ovarian function of every patient will be\n      repeatedly evaluated in relation with toxicity of chemotherapy used. These ovarian function\n      results will be compared with control group of patients without gonadal protection, which\n      reproductive functions will be evaluated according the same method."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  diagnosis of Hodgkin lymphoma\n\n          -  FSH and LH levels in peripheral blood below 15 IU/l\n\n          -  fertile age from 18 to 35 years\n\n          -  female\n\n          -  presence of both ovaries\n\n        Exclusion Criteria:\n\n          -  ovarian tumours or cysts over 40 mm in diameter"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "35 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "72", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 30, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01764230", 
            "org_study_id": "Masaryk University"
        }, 
        "intervention": {
            "arm_group_label": "case group", 
            "description": "Throughout the course of chemotherapy, patients were administered triptorelin (Diphereline SR 3 mg, Ibsen) in the form of i.m. injections, always once a month and simultaneously with the chemotherapy.", 
            "intervention_name": "triptorelin", 
            "intervention_type": "Drug", 
            "other_name": "triptorelin (Diphereline SR 3 mg, Ibsen)"
        }, 
        "intervention_browse": {
            "mesh_term": "Triptorelin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Hodgkin lymphoma", 
            "Hodgkin disease"
        ], 
        "lastchanged_date": "January 7, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Brno", 
                    "country": "Czech Republic", 
                    "zip": "62500"
                }, 
                "name": "Brno University Hospital and Masaryk University School of Medicine"
            }
        }, 
        "location_countries": {
            "country": "Czech Republic"
        }, 
        "number_of_arms": "2", 
        "official_title": "Prevention of Ovarian Function Damage by a GnRH Analogue During Chemotherapy in Hodgkin Lymphoma Patients", 
        "overall_official": {
            "affiliation": "Masaryk University", 
            "last_name": "Martin Huser, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Czech Republic: Grant Agency of the Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2007", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Premature ovarian failure defined as levels of FSH over 15 IU/l in peripheral blood.", 
                "measure": "Premature ovarian failure after chemotherapy", 
                "safety_issue": "No", 
                "time_frame": "6 months after the end of chemotherapy"
            }, 
            {
                "description": "Premature ovarian failure defined as levels of FSH over 15 IU/l in peripheral blood.", 
                "measure": "Premature ovarian failure after chemotherapy", 
                "safety_issue": "No", 
                "time_frame": "12 months after the end of chemotherapy"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01764230"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Masaryk University", 
            "investigator_full_name": "Martin Huser", 
            "investigator_title": "MD, PhD.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "results_reference": {
            "PMID": "18258763", 
            "citation": "Huser M, Crha I, Ventruba P, Hudecek R, Zakova J, Smardova L, Kral Z, Jarkovsky J. Prevention of ovarian function damage by a GnRH analogue during chemotherapy in Hodgkin lymphoma patients. Hum Reprod. 2008 Apr;23(4):863-8. doi: 10.1093/humrep/den005. Epub 2008 Feb 7."
        }, 
        "secondary_outcome": [
            {
                "description": "A - ABVD 4x Adriamycin, bleomycin, vinblastin and dacarbazin\nB Combination of ABVD and BEACOPP regimens 4x  Adriamycin, bleomycin, vinblastin and dacarbazin\u00febleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone\nC BEACOPP regimen 8x - Bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone", 
                "measure": "Rate of premature ovarian failure according to the degree of toxicity of the chemotherapeutic regimen", 
                "safety_issue": "No", 
                "time_frame": "6 months after the end of chemotherapy"
            }, 
            {
                "description": "A - ABVD 4x Adriamycin, bleomycin, vinblastin and dacarbazin\nB Combination of ABVD and BEACOPP regimens 4x  Adriamycin, bleomycin, vinblastin and dacarbazin\u00febleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone\nC BEACOPP regimen 8x - Bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone", 
                "measure": "Rate of premature ovarian failure according to the degree of toxicity of the chemotherapeutic regimen", 
                "safety_issue": "No", 
                "time_frame": "12 month after chemotherapy"
            }
        ], 
        "source": "Masaryk University", 
        "sponsors": {
            "collaborator": {
                "agency": "Grant Agency of the Ministry of Health of the Czech Republic", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Masaryk University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2004", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}